Paget Disease Treatment Market Report 2026

The paget disease treatment market size has grown steadily in recent years. It will grow from $2.19 billion in 2025 to $2.27 billion in 2026 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to limited treatment options for paget's disease, reliance on conventional bisphosphonates, growing prevalence of bone disorders, lack of patient awareness about disease management, hospital-centric treatment models.

The paget disease treatment market size is expected to see steady growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to emergence of novel paget disease therapies, increasing adoption of targeted drug formulations, growth in minimally invasive surgical procedures, rising telehealth adoption for chronic bone disorders, expansion of online and retail pharmacy distribution channels. Major trends in the forecast period include rising adoption of bisphosphonate therapies, integration of personalized medicine approaches, growth in minimally invasive surgical interventions, increasing use of telemedicine for bone disorder management, expansion of online pharmacies for treatment access.

The increasing number of cases related to arthritis and bone injuries is expected to drive growth in the Paget disease treatment market in the coming years. Arthritis, which causes joint inflammation, and bone injuries are influenced by reduced physical activity, weakening muscles and joints and lowering their capacity to support movement and absorb impact. This elevates the risk of joint degeneration, stiffness, and fractures over time. Treatments for Paget disease help manage arthritis and bone injuries by alleviating bone pain, improving joint function, and preventing complications such as fractures and deformities resulting from abnormal bone remodeling. For example, in February 2024, Arthritis Australia, an Australia-based nonprofit focused on arthritis awareness and support, reported that approximately 15% of Australians across all age groups live with arthritis, making it one of the country’s most common chronic health conditions. Projections suggest that the arthritis patient population will rise to 5.39 million by 2040, a 31% increase representing 1.28 million additional individuals affected. By 2040, the number of people with rheumatoid arthritis is expected to reach 280,040 males and 479,828 females. Therefore, the rise in arthritis and bone injuries is fueling demand for Paget disease treatment.

Companies in the Paget disease treatment market are focusing on innovative product development, such as calcium regulators, to enhance treatment effectiveness, improve patient outcomes, and expand market reach. Calcium regulators are medications that maintain proper calcium levels in the blood and bones, supporting essential physiological functions. For instance, in February 2025, Fresenius Kabi AG, a Germany-based healthcare company, launched Calcitonin Salmon Injection, USP Synthetic, a calcium regulator aimed at treating symptomatic Paget’s disease, hypercalcemia, and postmenopausal osteoporosis. This product offers a cost-effective treatment option, strengthens the supply chain, and expands the company’s portfolio of generic injectables. Fresenius Kabi has invested heavily in its facilities to ensure consistent medicine supply, improve patient care, and solidify its position as a leading healthcare provider.

In June 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Taro Pharmaceutical for approximately $347.73 million. This acquisition gives Sun Pharma full control of Taro Pharmaceutical Industries Ltd., enhancing its dermatology and specialty generics portfolio while streamlining operations and maximizing synergies. Taro Pharmaceutical Industries Ltd., based in Israel, specializes in generic and specialty medicines, including treatments for Paget’s disease.

Major companies operating in the paget disease treatment market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Limited, Apotex Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Zakłady Farmaceutyczne Polpharma S.A., Amgen Inc., Sanofi S.A., GlaxoSmithKline plc, Johnson & Johnson, Roche Holding AG, AstraZeneca, Mallinckrodt Pharmaceuticals, Neopharma Inc., Kyowa Kirin Co. Ltd., Radius Health Inc., Accord Healthcare Ltd., Leucadia Pharmaceuticals Inc., Biocon Ltd., Omeros Corp., Angitia Biopharmaceuticals, CSPC Pharmaceutical Group Ltd., Luye Pharma Group Ltd.

North America was the largest region in the paget disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paget disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the paget disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the paget disease treatment market by increasing costs for imported medications, therapeutic agents, and delivery devices. Hospital pharmacies, retail pharmacies, and online channels in regions like north america, europe, and asia-pacific are most affected due to dependency on imported drugs. While tariffs have increased procurement expenses, they have also encouraged local manufacturing, stimulated investment in domestic production, and promoted innovation in minimally invasive and telehealth-enabled treatment solutions.

The paget disease treatment market research report is one of a series of new reports that provides paget disease treatment market statistics, including paget disease treatment industry global market size, regional shares, competitors with a paget disease treatment market share, detailed paget disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the paget disease treatment industry. This paget disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Paget's disease is a chronic bone disorder marked by abnormal bone remodeling, which results in weakened and enlarged bones. Treatment generally involves medications to regulate bone metabolism and manage symptoms, along with pain relievers and, in severe cases, surgical intervention for bone deformities.

The main treatments for Paget’s disease include Actonel, Reclast, Zoledronic acid, Fosamax, Miacalcin, Aredia, Calcitonin, Zometa, and other therapies. Actonel, for example, is the brand name for risedronate, used to treat and prevent osteoporosis by strengthening bones. These treatments are administered through various routes, including oral, intravenous, and topical methods, and are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The primary end users include hospitals, clinics, and other healthcare providers.

The paget disease treatment market consists of revenues earned by entities by providing services such as diagnosis services, orthopedic services, genetic counseling services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paget disease treatment market also includes sales of pain management medications, calcium and vitamin D supplements, bone density monitoring devices, and assistive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.